The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.
作者信息
Wolfson J S, Hooper D C
出版信息
Antimicrob Agents Chemother. 1985 Oct;28(4):581-6. doi: 10.1128/AAC.28.4.581.
Abstract
摘要
相似文献
1
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.
Antimicrob Agents Chemother. 1985 Oct;28(4):581-6. doi: 10.1128/AAC.28.4.581.
2
Quinolones: pharmacology.
Pharm Weekbl Sci. 1986 Feb 21;8(1):22-5. doi: 10.1007/BF01975474.
3
[Fluoroquinolones. 1. Their chemical structure, mechanism of action and antibacterial activity].
Dtsch Med Wochenschr. 1988 Apr 22;113(16):648-51. doi: 10.1055/s-2008-1067700.
4
[Gyrase inhibitor].
Klin Wochenschr. 1985 Oct 1;63(19):1036-9. doi: 10.1007/BF01737642.
5
[Mechanism of action of quinolones].
Infection. 1986;14 Suppl 1:S3-15. doi: 10.1007/BF01645191.
6
Mode of action, and in vitro and in vivo activities of the fluoroquinolones.
J Clin Pharmacol. 1988 Feb;28(2):156-68. doi: 10.1002/j.1552-4604.1988.tb05967.x.
7
Comparative in vitro activity of the new quinolone CI-934.
Eur J Clin Microbiol. 1986 Jun;5(3):343-5. doi: 10.1007/BF02017794.
8
Computer automated structure evaluation of quinolone antibacterial agents.
Antimicrob Agents Chemother. 1987 Nov;31(11):1831-40. doi: 10.1128/AAC.31.11.1831.
9
In vitro evaluation of A-56619 and A-56620, two new quinolones.
Antimicrob Agents Chemother. 1986 Jan;29(1):40-3. doi: 10.1128/AAC.29.1.40.
10
Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620.
Antimicrob Agents Chemother. 1986 Jul;30(1):143-6. doi: 10.1128/AAC.30.1.143.
引用本文的文献
1
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design.
Pharmaceuticals (Basel). 2025 Apr 22;18(5):607. doi: 10.3390/ph18050607.
2
Antibiotic type and dose variably affect microbiomes of a disease-resistant Acropora cervicornis genotype.
Environ Microbiome. 2025 May 2;20(1):46. doi: 10.1186/s40793-025-00709-2.
3
Green Approach for Simultaneous Quantitative Analysis of Fluoroquinolones in the Environment using Three-Dimensional Fluorescence Coupled with Second-Order Calibration Method.
J Fluoresc. 2025 Jun;35(6):4789-4801. doi: 10.1007/s10895-024-03879-3. Epub 2024 Aug 10.
4
Contribution of the SOS response and the DNA repair systems to norfloxacin induced mutations in .
Mar Life Sci Technol. 2023 Sep 21;5(4):538-550. doi: 10.1007/s42995-023-00185-y. eCollection 2023 Nov.
5
Essential Oil: Natural Antioxidant as an Effective Antimicrobial and Anti-Inflammatory Agent.
Antioxidants (Basel). 2023 Sep 27;12(10):1807. doi: 10.3390/antiox12101807.
6
Efflux pump inhibitory potential of indole derivatives as an arsenal against over-expressing .
Microbiol Spectr. 2023 Sep 27;11(5):e0487622. doi: 10.1128/spectrum.04876-22.
7
Fluoroquinolone Analogs, SAR Analysis, and the Antimicrobial Evaluation of 7-Benzimidazol-1-yl-fluoroquinolone in In Vitro, In Silico, and In Vivo Models.
Molecules. 2023 Aug 11;28(16):6018. doi: 10.3390/molecules28166018.
8
Enrofloxacin Poisoning: A Rare Occurrence in Children.
Indian J Pediatr. 2023 Mar;90(3):306. doi: 10.1007/s12098-022-04450-3. Epub 2023 Jan 10.
9
Metal-Organic Framework-Based Composites for the Detection and Monitoring of Pharmaceutical Compounds in Biological and Environmental Matrices.
Water Air Soil Pollut. 2022;233(12):493. doi: 10.1007/s11270-022-05904-2. Epub 2022 Nov 23.
10
aqueous extract protects against norfloxacin-induced hepato-nephrotoxicity in rats.
Chin Herb Med. 2019 Dec 28;12(2):156-162. doi: 10.1016/j.chmed.2019.09.007. eCollection 2020 Apr.
本文引用的文献
1
Nalidixic Acid and the Metabolism of Escherichia coli.
J Bacteriol. 1970 Dec;104(3):1168-75. doi: 10.1128/jb.104.3.1168-1175.1970.
2
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.
J Med Chem. 1980 Dec;23(12):1358-63. doi: 10.1021/jm00186a014.
3
Types of spontaneous nalidixic acid resistant mutants of Escherichia coli.
Indian J Exp Biol. 1980 Apr;18(4):341-3.
4
In vitro and in vivo activity of DL-8280, a new oxazine derivative.
Antimicrob Agents Chemother. 1982 Oct;22(4):548-53. doi: 10.1128/AAC.22.4.548.
5
Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes.
Antimicrob Agents Chemother. 1982 Aug;22(2):242-9. doi: 10.1128/AAC.22.2.242.
6
[Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].
Pathol Biol (Paris). 1982 Jun;30(6):394-7.
7
Cinoxacin (Cinobac, Eli Lilly & Co.).
Drug Intell Clin Pharm. 1982 Dec;16(12):916-21. doi: 10.1177/106002808201601203.
8
In vitro antibiotic susceptibility of Legionellaceae: search for alternative antimicrobial drugs.
Chemotherapy. 1984;30(3):182-7. doi: 10.1159/000238266.
9
In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.
Antimicrob Agents Chemother. 1984 Apr;25(4):518-21. doi: 10.1128/AAC.25.4.518.
10
Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens.
Antimicrob Agents Chemother. 1984 Apr;25(4):504-6. doi: 10.1128/AAC.25.4.504.
Zotero 插件